Use of Prostaglandin E2 for Cervical Ripening in Pregnancies with Oligohydramnios
The effectiveness of intracervical prostaglandin E2 (PGE2) was studied in 96 primigravidas with unfavorable cervix and need for induction of labor. Group A consisted of 49 oligohydramnios and group B of 47 cases with normal amniotic fluid volume (controls). A single dose of 0.5 mg PGE2 gel was appli...
Gespeichert in:
| Veröffentlicht in: | Gynecologic and obstetric investigation 2000-01, Vol.50 (3), p.158-161 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 161 |
|---|---|
| container_issue | 3 |
| container_start_page | 158 |
| container_title | Gynecologic and obstetric investigation |
| container_volume | 50 |
| creator | Stefos, Theodor Mouzakioti, Elena Sotiriadis, Alexandros Andronikou, Styliani Adamidis, Konstantinos Lolis, Dimitrios |
| description | The effectiveness of intracervical prostaglandin E2 (PGE2) was studied in 96 primigravidas with unfavorable cervix and need for induction of labor. Group A consisted of 49 oligohydramnios and group B of 47 cases with normal amniotic fluid volume (controls). A single dose of 0.5 mg PGE2 gel was applied intracervically and several parameters were recorded during the next hours. The mean number of uterine contractions increased during the first 2 h in both groups, decreased during the next one and did not change significantly afterwards. The mean fetal heart rate (FHR) in group A decreased during the first 2 h and then increased, staying always within normal limits. The mean FHR in group B increased for 2 h, decreased during the next hour and did not change significantly afterwards. No significant differences were found between the two groups regarding mode of delivery, Apgar score and neonatal acidosis. Intracervical PGE2 appeared to effectively stimulate cervical ripening and labor induction in oligohydramnios, without causing side effects to the uterus and fetus. |
| doi_str_mv | 10.1159/000010316 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_72300319</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>677506821</sourcerecordid><originalsourceid>FETCH-LOGICAL-c384t-8bbbaa58bc6472bf5fde5c0bc7a487dcd03deb9f5dbe43e74e033f6c0eb194da3</originalsourceid><addsrcrecordid>eNpt0EtLAzEUBeAgitbHwrUgQURwMZpMknkspdQHFKqi4G7I42Yanc7UpFX67422WBCzyeJ-3JwchA4puaBUlJckHkoYzTZQj_KUJYSkL5uoR1heJDnj2Q7aDeE1IlEWfBvtUEooL3nWQw_PAXBn8b3vwkzWjWyNa_EgxbbzuA_-w2nZ4Ec3hda1NY6zew91K1vtIOBPNxvjUePqbrwwXk5a14V9tGVlE-Bgde-h5-vBU_82GY5u7vpXw0Szgs-SQiklpSiUznieKiusAaGJ0rnkRW60IcyAKq0wCjiDnANhzGaagKIlN5LtobPl3qnv3ucQZtXEBQ1N_AJ081DlKSOxkzLCkz_wtZv7Nmar0pTlmRAkjeh8iXQsIniw1dS7ifSLipLqu-Tqt-Roj1cL52oCZi1XrUZwugIyxPqs_64rrJ0grGRiHexN-hr87_xmdPfzUDU1NqKjf9EyyhcwfZgi</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>223765502</pqid></control><display><type>article</type><title>Use of Prostaglandin E2 for Cervical Ripening in Pregnancies with Oligohydramnios</title><source>MEDLINE</source><source>Karger Journals</source><creator>Stefos, Theodor ; Mouzakioti, Elena ; Sotiriadis, Alexandros ; Andronikou, Styliani ; Adamidis, Konstantinos ; Lolis, Dimitrios</creator><creatorcontrib>Stefos, Theodor ; Mouzakioti, Elena ; Sotiriadis, Alexandros ; Andronikou, Styliani ; Adamidis, Konstantinos ; Lolis, Dimitrios</creatorcontrib><description>The effectiveness of intracervical prostaglandin E2 (PGE2) was studied in 96 primigravidas with unfavorable cervix and need for induction of labor. Group A consisted of 49 oligohydramnios and group B of 47 cases with normal amniotic fluid volume (controls). A single dose of 0.5 mg PGE2 gel was applied intracervically and several parameters were recorded during the next hours. The mean number of uterine contractions increased during the first 2 h in both groups, decreased during the next one and did not change significantly afterwards. The mean fetal heart rate (FHR) in group A decreased during the first 2 h and then increased, staying always within normal limits. The mean FHR in group B increased for 2 h, decreased during the next hour and did not change significantly afterwards. No significant differences were found between the two groups regarding mode of delivery, Apgar score and neonatal acidosis. Intracervical PGE2 appeared to effectively stimulate cervical ripening and labor induction in oligohydramnios, without causing side effects to the uterus and fetus.</description><identifier>ISSN: 0378-7346</identifier><identifier>EISSN: 1423-002X</identifier><identifier>DOI: 10.1159/000010316</identifier><identifier>PMID: 11014946</identifier><identifier>CODEN: GOBIDS</identifier><language>eng</language><publisher>Basel, Switzerland: Karger</publisher><subject>Biological and medical sciences ; Cervical Ripening - drug effects ; Dinoprostone - administration & dosage ; Dinoprostone - therapeutic use ; Female ; Genital system. Reproduction ; Humans ; Medical sciences ; Oligohydramnios ; Original Paper ; Oxytocics - administration & dosage ; Oxytocics - therapeutic use ; Pharmacology. Drug treatments ; Pregnancy ; Pregnancy Outcome</subject><ispartof>Gynecologic and obstetric investigation, 2000-01, Vol.50 (3), p.158-161</ispartof><rights>2000 S. Karger AG, Basel</rights><rights>2000 INIST-CNRS</rights><rights>Copyright 2000 S. Karger AG, Basel</rights><rights>Copyright (c) 2000 S. Karger AG, Basel</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c384t-8bbbaa58bc6472bf5fde5c0bc7a487dcd03deb9f5dbe43e74e033f6c0eb194da3</citedby><cites>FETCH-LOGICAL-c384t-8bbbaa58bc6472bf5fde5c0bc7a487dcd03deb9f5dbe43e74e033f6c0eb194da3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,2429,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1503935$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11014946$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Stefos, Theodor</creatorcontrib><creatorcontrib>Mouzakioti, Elena</creatorcontrib><creatorcontrib>Sotiriadis, Alexandros</creatorcontrib><creatorcontrib>Andronikou, Styliani</creatorcontrib><creatorcontrib>Adamidis, Konstantinos</creatorcontrib><creatorcontrib>Lolis, Dimitrios</creatorcontrib><title>Use of Prostaglandin E2 for Cervical Ripening in Pregnancies with Oligohydramnios</title><title>Gynecologic and obstetric investigation</title><addtitle>Gynecol Obstet Invest</addtitle><description>The effectiveness of intracervical prostaglandin E2 (PGE2) was studied in 96 primigravidas with unfavorable cervix and need for induction of labor. Group A consisted of 49 oligohydramnios and group B of 47 cases with normal amniotic fluid volume (controls). A single dose of 0.5 mg PGE2 gel was applied intracervically and several parameters were recorded during the next hours. The mean number of uterine contractions increased during the first 2 h in both groups, decreased during the next one and did not change significantly afterwards. The mean fetal heart rate (FHR) in group A decreased during the first 2 h and then increased, staying always within normal limits. The mean FHR in group B increased for 2 h, decreased during the next hour and did not change significantly afterwards. No significant differences were found between the two groups regarding mode of delivery, Apgar score and neonatal acidosis. Intracervical PGE2 appeared to effectively stimulate cervical ripening and labor induction in oligohydramnios, without causing side effects to the uterus and fetus.</description><subject>Biological and medical sciences</subject><subject>Cervical Ripening - drug effects</subject><subject>Dinoprostone - administration & dosage</subject><subject>Dinoprostone - therapeutic use</subject><subject>Female</subject><subject>Genital system. Reproduction</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>Oligohydramnios</subject><subject>Original Paper</subject><subject>Oxytocics - administration & dosage</subject><subject>Oxytocics - therapeutic use</subject><subject>Pharmacology. Drug treatments</subject><subject>Pregnancy</subject><subject>Pregnancy Outcome</subject><issn>0378-7346</issn><issn>1423-002X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNpt0EtLAzEUBeAgitbHwrUgQURwMZpMknkspdQHFKqi4G7I42Yanc7UpFX67422WBCzyeJ-3JwchA4puaBUlJckHkoYzTZQj_KUJYSkL5uoR1heJDnj2Q7aDeE1IlEWfBvtUEooL3nWQw_PAXBn8b3vwkzWjWyNa_EgxbbzuA_-w2nZ4Ec3hda1NY6zew91K1vtIOBPNxvjUePqbrwwXk5a14V9tGVlE-Bgde-h5-vBU_82GY5u7vpXw0Szgs-SQiklpSiUznieKiusAaGJ0rnkRW60IcyAKq0wCjiDnANhzGaagKIlN5LtobPl3qnv3ucQZtXEBQ1N_AJ081DlKSOxkzLCkz_wtZv7Nmar0pTlmRAkjeh8iXQsIniw1dS7ifSLipLqu-Tqt-Roj1cL52oCZi1XrUZwugIyxPqs_64rrJ0grGRiHexN-hr87_xmdPfzUDU1NqKjf9EyyhcwfZgi</recordid><startdate>20000101</startdate><enddate>20000101</enddate><creator>Stefos, Theodor</creator><creator>Mouzakioti, Elena</creator><creator>Sotiriadis, Alexandros</creator><creator>Andronikou, Styliani</creator><creator>Adamidis, Konstantinos</creator><creator>Lolis, Dimitrios</creator><general>Karger</general><general>S. Karger AG</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20000101</creationdate><title>Use of Prostaglandin E2 for Cervical Ripening in Pregnancies with Oligohydramnios</title><author>Stefos, Theodor ; Mouzakioti, Elena ; Sotiriadis, Alexandros ; Andronikou, Styliani ; Adamidis, Konstantinos ; Lolis, Dimitrios</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c384t-8bbbaa58bc6472bf5fde5c0bc7a487dcd03deb9f5dbe43e74e033f6c0eb194da3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Biological and medical sciences</topic><topic>Cervical Ripening - drug effects</topic><topic>Dinoprostone - administration & dosage</topic><topic>Dinoprostone - therapeutic use</topic><topic>Female</topic><topic>Genital system. Reproduction</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>Oligohydramnios</topic><topic>Original Paper</topic><topic>Oxytocics - administration & dosage</topic><topic>Oxytocics - therapeutic use</topic><topic>Pharmacology. Drug treatments</topic><topic>Pregnancy</topic><topic>Pregnancy Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Stefos, Theodor</creatorcontrib><creatorcontrib>Mouzakioti, Elena</creatorcontrib><creatorcontrib>Sotiriadis, Alexandros</creatorcontrib><creatorcontrib>Andronikou, Styliani</creatorcontrib><creatorcontrib>Adamidis, Konstantinos</creatorcontrib><creatorcontrib>Lolis, Dimitrios</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Biotechnology Research Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Gynecologic and obstetric investigation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Stefos, Theodor</au><au>Mouzakioti, Elena</au><au>Sotiriadis, Alexandros</au><au>Andronikou, Styliani</au><au>Adamidis, Konstantinos</au><au>Lolis, Dimitrios</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Use of Prostaglandin E2 for Cervical Ripening in Pregnancies with Oligohydramnios</atitle><jtitle>Gynecologic and obstetric investigation</jtitle><addtitle>Gynecol Obstet Invest</addtitle><date>2000-01-01</date><risdate>2000</risdate><volume>50</volume><issue>3</issue><spage>158</spage><epage>161</epage><pages>158-161</pages><issn>0378-7346</issn><eissn>1423-002X</eissn><coden>GOBIDS</coden><abstract>The effectiveness of intracervical prostaglandin E2 (PGE2) was studied in 96 primigravidas with unfavorable cervix and need for induction of labor. Group A consisted of 49 oligohydramnios and group B of 47 cases with normal amniotic fluid volume (controls). A single dose of 0.5 mg PGE2 gel was applied intracervically and several parameters were recorded during the next hours. The mean number of uterine contractions increased during the first 2 h in both groups, decreased during the next one and did not change significantly afterwards. The mean fetal heart rate (FHR) in group A decreased during the first 2 h and then increased, staying always within normal limits. The mean FHR in group B increased for 2 h, decreased during the next hour and did not change significantly afterwards. No significant differences were found between the two groups regarding mode of delivery, Apgar score and neonatal acidosis. Intracervical PGE2 appeared to effectively stimulate cervical ripening and labor induction in oligohydramnios, without causing side effects to the uterus and fetus.</abstract><cop>Basel, Switzerland</cop><pub>Karger</pub><pmid>11014946</pmid><doi>10.1159/000010316</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0378-7346 |
| ispartof | Gynecologic and obstetric investigation, 2000-01, Vol.50 (3), p.158-161 |
| issn | 0378-7346 1423-002X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_72300319 |
| source | MEDLINE; Karger Journals |
| subjects | Biological and medical sciences Cervical Ripening - drug effects Dinoprostone - administration & dosage Dinoprostone - therapeutic use Female Genital system. Reproduction Humans Medical sciences Oligohydramnios Original Paper Oxytocics - administration & dosage Oxytocics - therapeutic use Pharmacology. Drug treatments Pregnancy Pregnancy Outcome |
| title | Use of Prostaglandin E2 for Cervical Ripening in Pregnancies with Oligohydramnios |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T11%3A13%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Use%20of%20Prostaglandin%20E2%20for%20Cervical%20Ripening%20in%20Pregnancies%20with%20Oligohydramnios&rft.jtitle=Gynecologic%20and%20obstetric%20investigation&rft.au=Stefos,%20Theodor&rft.date=2000-01-01&rft.volume=50&rft.issue=3&rft.spage=158&rft.epage=161&rft.pages=158-161&rft.issn=0378-7346&rft.eissn=1423-002X&rft.coden=GOBIDS&rft_id=info:doi/10.1159/000010316&rft_dat=%3Cproquest_cross%3E677506821%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=223765502&rft_id=info:pmid/11014946&rfr_iscdi=true |